Literature DB >> 17981370

Novel 9-oxo-thiazolo[5,4-f]quinazoline-2-carbonitrile derivatives as dual cyclin-dependent kinase 1 (CDK1)/glycogen synthase kinase-3 (GSK-3) inhibitors: synthesis, biological evaluation and molecular modeling studies.

Cédric Logé1, Alexandra Testard, Valérie Thiéry, Olivier Lozach, Mélina Blairvacq, Jean-Michel Robert, Laurent Meijer, Thierry Besson.   

Abstract

Continuous efforts in microwave-assisted synthesis and the structure-activity relationships' (SARs) studies of novel modified 9-oxo-thiazolo[5,4-f]quinazoline-2-carbonitriles, allowed identification of new amidine and imidate derivatives as potent and dual CDK1/GSK-3 inhibitors. Combination of lead optimization and molecular modeling studies allowed identification of a dual CDK1/GSK-3 inhibitor (compound 13d) with submicromolar values.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17981370     DOI: 10.1016/j.ejmech.2007.09.020

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  15 in total

Review 1.  Glycogen synthase kinase 3: more than a namesake.

Authors:  Geetha Vani Rayasam; Vamshi Krishna Tulasi; Reena Sodhi; Joseph Alex Davis; Abhijit Ray
Journal:  Br J Pharmacol       Date:  2009-03-04       Impact factor: 8.739

2.  Organocatalysis in heterocyclic synthesis: DABCO as a mild and efficient catalytic system for the synthesis of a novel class of quinazoline, thiazolo [3,2-a]quinazoline and thiazolo[2,3-b] quinazoline derivatives.

Authors:  Haider Behbehani; Hamada Mohamed Ibrahim
Journal:  Chem Cent J       Date:  2013-05-07       Impact factor: 4.215

3.  GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS.

Authors:  Hagit Eldar-Finkelman; Ana Martinez
Journal:  Front Mol Neurosci       Date:  2011-10-31       Impact factor: 5.639

Review 4.  Chemical characteristics, synthetic methods, and biological potential of quinazoline and quinazolinone derivatives.

Authors:  Mohammad Asif
Journal:  Int J Med Chem       Date:  2014-11-12

5.  Potential biomarkers and therapeutic targets in cervical cancer: Insights from the meta-analysis of transcriptomics data within network biomedicine perspective.

Authors:  Medi Kori; Kazim Yalcin Arga
Journal:  PLoS One       Date:  2018-07-18       Impact factor: 3.240

6.  Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part II.

Authors:  Alicia Foucourt; Damien Hédou; Carole Dubouilh-Benard; Angélique Girard; Thierry Taverne; Anne-Sophie Casagrande; Laurent Désiré; Bertrand Leblond; Thierry Besson
Journal:  Molecules       Date:  2014-09-26       Impact factor: 4.411

7.  Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part I.

Authors:  Alicia Foucourt; Damien Hédou; Carole Dubouilh-Benard; Laurent Désiré; Anne-Sophie Casagrande; Bertrand Leblond; Nadège Loäec; Laurent Meijer; Thierry Besson
Journal:  Molecules       Date:  2014-09-29       Impact factor: 4.411

8.  Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models.

Authors:  Thomas Kramer; Boris Schmidt; Fabio Lo Monte
Journal:  Int J Alzheimers Dis       Date:  2012-07-22

9.  4-Aminoethylamino-emodin--a novel potent inhibitor of GSK-3beta--acts as an insulin-sensitizer avoiding downstream effects of activated beta-catenin.

Authors:  Rolf Gebhardt; Katja S Lerche; Frank Götschel; Robert Günther; Jens Kolander; Lars Teich; Sebastian Zellmer; Hans-Jörg Hofmann; Kurt Eger; Andreas Hecht; Frank Gaunitz
Journal:  J Cell Mol Med       Date:  2009-10-03       Impact factor: 5.310

10.  Synthesis of 2-Mercapto-(2-Oxoindolin-3-Ylidene)Acetonitriles from 3-(4-Chloro-5H-1,2,3-Dithiazol-5-Ylidene)Indolin-2-ones.

Authors:  Boris Letribot; Régis Delatouche; Hervé Rouillard; Antoine Bonnet; Jean-René Chérouvrier; Lisianne Domon; Thierry Besson; Valérie Thiéry
Journal:  Molecules       Date:  2018-06-08       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.